[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614514":3},{"organization":4,"outcomesModule":7,"designInfo":50,"detailedDescription":63,"studyPopulation":55,"armGroups":64,"interventions":75,"overallOfficials":55,"centralContacts":84,"locations":92,"responsibleParty":458,"collaborators":463,"id":466,"slug":55,"hasResults":467,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":467,"sex":472,"minAge":473,"maxAge":474,"enrollmentInfo":475,"targetDuration":55,"studyType":478,"phases":479,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":111,"whyStopped":55,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":503},{"fullName":5,"class":6},"University of Cologne","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":33},[9],{"measure":10,"description":11,"timeFrame":12},"Chronic eGFR slope","The annual chronic eGFR slope will be calculated using all available serum creatinine values from week 6 to week 156 (end of treatment), using linear mixed models.","week 6 up to week 156 (end of treatment)",[14,18,22,26,29],{"measure":15,"description":16,"timeFrame":17},"Change in eGFR from pre-treatment to post-treatment (off-treatment values)","Change in kidney function will be assessed by comparing the mean eGFR values before treatment (calculated as the average of serum creatinine measurements at week -4 and week 0) with the mean eGFR values after treatment (calculated as the average of measurements at week 162 and week 168). The difference between these two timepoints represents the off-treatment change in kidney function.","Week -4 to Week 168",{"measure":19,"description":20,"timeFrame":21},"Time to first occurrence of a composite renal endpoint","Time from randomization to the first occurrence of any of the following events:\n\n1. A sustained ≥40% decrease in eGFR from randomization, confirmed by a second measurement at the next scheduled visit or measured at the last scheduled visit before death or study end.\n2. End-stage kidney disease (ESKD), defined as initiation of chronic dialysis, kidney transplantation, or a sustained eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m².\n3. Renal death.","From randomization (week 0) until end of follow-up (up to week 168)",{"measure":23,"description":24,"timeFrame":25},"Incidence of serious adverse events (SAEs)","All serious adverse events (SAEs) will be collected.","From randomization (week 0) until end of follow-up (week 168)",{"measure":27,"description":28,"timeFrame":25},"Incidence of adverse events of special interest (AESIs)","All adverse events of special interest (AESIs) will be collected.",{"measure":30,"description":31,"timeFrame":32},"Change in total kidney volume (TKV) after 1 year","In the first 150 enrolled participants, total kidney volume (TKV) will be measured at baseline and at week 48 using standardized MRI protocols. The change in TKV over 48 weeks will be used to assess potential effects of dapagliflozin on kidney size.","Baseline (week -4 until week 0) to week 48 (first 150 patients)",[34,38,42,46],{"measure":35,"description":36,"timeFrame":37},"Change in kidney function based on cystatin-C measurements","Annual slopes of eGFR decline (in mL\u002Fmin\u002F1,73m2 per year), as calculated with linear mixed models using all available cystatin-c values:\n\n1. on-treatment between week 6 and EOT (week 156)\n2. off-treatment: before treatment (week -4 and week 0) and after treatment (week 162 and week 168)\n3. between baseline and EOT (week 0-156)","week -4 until EOS (week 168)",{"measure":39,"description":40,"timeFrame":41},"Changes in albuminuria","Worsening (increase \\>50% in comparison to baseline) or new onset of albuminuria (defined as \\>30mg albumin\u002Fg creatinine)","from randomization (week 0) until EOT (week 156)",{"measure":43,"description":44,"timeFrame":45},"Incidence of kidney stones","Number of symptomatic kidney stones (number of symptomatic episodes)","from randomization (week 0) until EOS (week 168)",{"measure":47,"description":48,"timeFrame":49},"Total eGFR slope","Total slope: annual slope of eGFR decline (in mL\u002Fmin\u002F1,73m2 per year), as calculated with linear mixed models, using all available creatinine values from baseline until end of treatment (week 0-156)","from randomization (week 0) until week 156",{"allocation":51,"interventionModel":52,"interventionModelDescription":53,"primaryPurpose":54,"observationalModel":55,"timePerspective":55,"maskingInfo":56},"RANDOMIZED","PARALLEL","Phase III, investigator-driven, multi-center, randomized, placebo-controlled, double-blind","TREATMENT",null,{"masking":57,"maskingDescription":55,"whoMasked":58},"QUADRUPLE",[59,60,61,62],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","ADPKD is a genetic disease characterized by the growth of fluid-filled renal cysts, leading to progressive loss of kidney function. SGLT2- inhibitors have recently become available for the treatment of chronic kidney disease (CKD). The landmark trials, which proved the positive effect of SGLT2-inhibitors in CKD, excluded patients with ADPKD. Accordingly, current ADPKD-guidelines do not recommend the use of SGLT2-inhibitors in ADPKD.\n\nThis investigator-driven, randomized, placebo-controlled, multi-center, double-blind trial will assess the effect of daily dapagliflozin (10mg) intake on the chronic eGFR-slope in 420 patients with ADPKD. As a secondary endpoint the study will assess a composite endpoint triggered by reaching either 40%-eGFR loss, kidney failure or renal death. Safety aspects will additionally be addressed by an interim safety analysis considering total kidney volume, eGFR and copeptin-levels.",[65,70],{"label":66,"type":67,"description":55,"interventionNames":68},"Dapagliflozin 10 mg","EXPERIMENTAL",[69],"Drug: Dapagliflozin 10 mg",{"label":71,"type":72,"description":55,"interventionNames":73},"Placebo","PLACEBO_COMPARATOR",[74],"Drug: Matching Placebo",[76,80],{"type":77,"name":66,"description":78,"armGroupLabels":79,"otherNames":55},"DRUG","Participants receive 10 mg of Dapagliflozin orally once daily for 36 months.",[66],{"type":77,"name":81,"description":82,"armGroupLabels":83,"otherNames":55},"Matching Placebo","Participants receive a matching placebo orally once daily for 36 months.",[71],[85,90],{"name":86,"role":87,"phone":88,"phoneExt":55,"email":89},"Roman-Ulrich Müller, Prof.","CONTACT","+49221478191005","STOP-PKD@uk-koeln.de",{"name":91,"role":87,"phone":88,"phoneExt":55,"email":89},"Philipp Scherrer, MD",[93,109,122,139,153,165,177,189,201,213,225,237,251,263,275,287,296,308,320,332,344,355,367,379,388,397,411,423,435,449],{"facility":94,"status":95,"city":96,"state":55,"zip":55,"country":97,"countryCode":98,"cosmosGeoPoint":99,"geoPoint":104,"contacts":105},"Vorarlberger Krankenhaus-Betriebsgesellschaft","NOT_YET_RECRUITING","Feldkirch","Austria","AT",{"type":100,"coordinates":101},"Point",[102,103],9.59734,47.23645,{"lat":103,"lon":102},[106],{"name":107,"role":87,"phone":55,"phoneExt":55,"email":108},"Emanuel Zitt, MD","nephro@lkhf.at",{"facility":110,"status":111,"city":112,"state":55,"zip":55,"country":97,"countryCode":98,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Medizinische Universitaet Innsbruck","RECRUITING","Innsbruck",{"type":100,"coordinates":114},[115,116],11.39454,47.26266,{"lat":116,"lon":115},[119],{"name":120,"role":87,"phone":55,"phoneExt":55,"email":121},"Michael Rudnicki, Prof.","michael.rudnicki@i-med.ac.at",{"facility":123,"status":95,"city":124,"state":125,"zip":126,"country":127,"countryCode":128,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Robert Bosch Gesellschaft für Medizinische Forschung mbH","Stuttgart","Baden-Wurttemberg","70376","Germany","DE",{"type":100,"coordinates":130},[131,132],9.17702,48.78232,{"lat":132,"lon":131},[135],{"name":136,"role":87,"phone":137,"phoneExt":55,"email":138},"Joerg Latus, Prof.","+4971181015874","andrea.schwab@rbk.de",{"facility":140,"status":95,"city":141,"state":142,"zip":143,"country":127,"countryCode":128,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Klinikum Nürnberg","Nuremberg","Bavaria","90471",{"type":100,"coordinates":145},[146,147],11.07752,49.45421,{"lat":147,"lon":146},[150],{"name":151,"role":87,"phone":152,"phoneExt":55,"email":55},"Christian Morath, Prof.","+499113982702",{"facility":154,"status":111,"city":155,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Universitaetsklinikum Aachen AöR","Aachen",{"type":100,"coordinates":157},[158,159],6.08342,50.77664,{"lat":159,"lon":158},[162],{"name":163,"role":87,"phone":55,"phoneExt":55,"email":164},"Susanne Fleig, MD","SekretariatMK2@ukaachen.de",{"facility":166,"status":111,"city":167,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Charite Universitaetsmedizin Berlin KöR","Berlin",{"type":100,"coordinates":169},[170,171],13.41053,52.52437,{"lat":171,"lon":170},[174],{"name":175,"role":87,"phone":55,"phoneExt":55,"email":176},"Eva Vanessa Schrezenmeier, Dr","nephrologie-studien@charite.de",{"facility":178,"status":111,"city":179,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"Universitätsklinikum Köln","Cologne",{"type":100,"coordinates":181},[182,183],6.95,50.93333,{"lat":183,"lon":182},[186],{"name":187,"role":87,"phone":55,"phoneExt":55,"email":188},"Malte Bartram, Dr.","studienzentrum-medII@uk-koeln.de",{"facility":190,"status":111,"city":191,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Klinikum Dortmund gGmbH","Dortmund",{"type":100,"coordinates":193},[194,195],7.466,51.51494,{"lat":195,"lon":194},[198],{"name":199,"role":87,"phone":55,"phoneExt":55,"email":200},"Fedai Özcan, MD","studienzentrum@klinikumdo.de",{"facility":202,"status":111,"city":203,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR","Dresden",{"type":100,"coordinates":205},[206,207],13.73832,51.05089,{"lat":207,"lon":206},[210],{"name":211,"role":87,"phone":55,"phoneExt":55,"email":212},"Alexander Paliege, MD","alexander.paliege@ukdd.de",{"facility":214,"status":95,"city":215,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":216,"geoPoint":220,"contacts":221},"Universitaetsklinikum Duesseldorf AöR","Düsseldorf",{"type":100,"coordinates":217},[218,219],6.77927,51.22319,{"lat":219,"lon":218},[222],{"name":223,"role":87,"phone":55,"phoneExt":55,"email":224},"Roman-Ulrich Mueller, Prof.","studienzentrum-nephrologie@med.uni-duesseldorf.de",{"facility":226,"status":111,"city":227,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":228,"geoPoint":232,"contacts":233},"Goethe University Frankfurt","Frankfurt",{"type":100,"coordinates":229},[230,231],10.53333,49.68333,{"lat":231,"lon":230},[234],{"name":235,"role":87,"phone":55,"phoneExt":55,"email":236},"Jeannine Lang, MD","sekretariat.nephrologie@unimedizin-ffm.de",{"facility":238,"status":95,"city":239,"state":55,"zip":240,"country":127,"countryCode":128,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"Medical Center - University of Freiburg","Freiburg im Breisgau","79106",{"type":100,"coordinates":242},[243,244],7.85222,47.9959,{"lat":244,"lon":243},[247],{"name":248,"role":87,"phone":249,"phoneExt":55,"email":250},"Jan Halbritter, Prof.","+4976127032510","jan.halbritter@uniklinik-freiburg.de",{"facility":252,"status":95,"city":253,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":254,"geoPoint":258,"contacts":259},"Universitaetsmedizin Goettingen","Göttingen",{"type":100,"coordinates":255},[256,257],9.93228,51.53443,{"lat":257,"lon":256},[260],{"name":261,"role":87,"phone":55,"phoneExt":55,"email":262},"Oliver Gross, Prof.","nephrorheuma.ambulanz@med.uni-goettingen.de",{"facility":264,"status":95,"city":265,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":266,"geoPoint":270,"contacts":271},"University Medical Center Hamburg-Eppendorf","Hamburg",{"type":100,"coordinates":267},[268,269],9.99302,53.55073,{"lat":269,"lon":268},[272],{"name":273,"role":87,"phone":55,"phoneExt":55,"email":274},"Fabian Braun, MD","nierenambulanz@uke.de",{"facility":276,"status":111,"city":277,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":278,"geoPoint":282,"contacts":283},"Medizinische Hochschule Hannover","Hanover",{"type":100,"coordinates":279},[280,281],9.73322,52.37052,{"lat":281,"lon":280},[284],{"name":285,"role":87,"phone":55,"phoneExt":55,"email":286},"Jessica Kaufeld, MD","studienzentrum@mh-hannover.de",{"facility":288,"status":95,"city":277,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":289,"geoPoint":291,"contacts":292},"Zentrum Fuer Nieren Hochdruck Und Stoffwechselerkrankungen",{"type":100,"coordinates":290},[280,281],{"lat":281,"lon":280},[293],{"name":294,"role":87,"phone":55,"phoneExt":55,"email":295},"Georg Schlieper, MD","Ambulanz.Heidering@dialyse-hannover.de",{"facility":297,"status":95,"city":298,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":299,"geoPoint":303,"contacts":304},"Universitaetsklinikum Heidelberg AöR","Heidelberg",{"type":100,"coordinates":300},[301,302],8.69079,49.40768,{"lat":302,"lon":301},[305],{"name":306,"role":87,"phone":55,"phoneExt":55,"email":307},"Claudia Sommerer, Prof.","Studienzentrum-Nephrologie.MED10@med.uni-heidelberg.de",{"facility":309,"status":111,"city":310,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":311,"geoPoint":315,"contacts":316},"Universitaetsklinikum Jena KöR","Jena",{"type":100,"coordinates":312},[313,314],11.5899,50.92878,{"lat":314,"lon":313},[317],{"name":318,"role":87,"phone":55,"phoneExt":55,"email":319},"Martin Busch, Prof.","kim3-nephroambulanz@med.uni-jena.de",{"facility":321,"status":95,"city":322,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":323,"geoPoint":327,"contacts":328},"Universitaetsklinikum Schleswig-Holstein AöR","Kiel",{"type":100,"coordinates":324},[325,326],10.13489,54.32133,{"lat":326,"lon":325},[329],{"name":330,"role":87,"phone":55,"phoneExt":55,"email":331},"Roland Schmitt, Prof.","studienzentrum.nephrologie.kiel@uksh.de",{"facility":333,"status":111,"city":334,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":335,"geoPoint":339,"contacts":340},"Universitaet Leipzig","Leipzig",{"type":100,"coordinates":336},[337,338],12.37129,51.33962,{"lat":338,"lon":337},[341],{"name":342,"role":87,"phone":55,"phoneExt":55,"email":343},"Friederike Petzold, MD","nephrologieambulanz@medizin.uni-leipzig.de",{"facility":321,"status":111,"city":345,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":346,"geoPoint":350,"contacts":351},"Lübeck",{"type":100,"coordinates":347},[348,349],10.68729,53.86893,{"lat":349,"lon":348},[352],{"name":353,"role":87,"phone":55,"phoneExt":55,"email":354},"Figen Cakiroglu, MD","Franziska.Klingbiel@uksh.de",{"facility":356,"status":111,"city":357,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":358,"geoPoint":362,"contacts":363},"Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR","Mainz",{"type":100,"coordinates":359},[360,361],8.28008,49.98185,{"lat":361,"lon":360},[364],{"name":365,"role":87,"phone":55,"phoneExt":55,"email":366},"Julia Weinmann-Menke, Prof.","julia.weinmann-menke@unimedizin-mainz.de",{"facility":368,"status":95,"city":369,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":370,"geoPoint":374,"contacts":375},"Klinikum der Technischen Universitaet Muenchen","München",{"type":100,"coordinates":371},[372,373],13.31243,51.60698,{"lat":373,"lon":372},[376],{"name":377,"role":87,"phone":55,"phoneExt":55,"email":378},"Lutz Renders, Prof.","nephrologie.office@mri.tum.de",{"facility":380,"status":111,"city":369,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":381,"geoPoint":383,"contacts":384},"LMU Klinikum Muenchen AöR",{"type":100,"coordinates":382},[372,373],{"lat":373,"lon":372},[385],{"name":386,"role":87,"phone":55,"phoneExt":55,"email":387},"Michael Fischereder, Prof.","NephroStudien-GH@med.uni-muenchen.de",{"facility":389,"status":111,"city":124,"state":55,"zip":55,"country":127,"countryCode":128,"cosmosGeoPoint":390,"geoPoint":392,"contacts":393},"Klinikum Der Landeshauptstadt Stuttgart gKAöR",{"type":100,"coordinates":391},[131,132],{"lat":132,"lon":131},[394],{"name":395,"role":87,"phone":55,"phoneExt":55,"email":396},"Markus Krautter, Dr.","m.krautter@klinikum-stuttgart.de",{"facility":398,"status":111,"city":399,"state":55,"zip":55,"country":400,"countryCode":401,"cosmosGeoPoint":402,"geoPoint":406,"contacts":407},"Universitair Medisch Centrum Groningen","Groningen","Netherlands","NL",{"type":100,"coordinates":403},[404,405],6.56667,53.21917,{"lat":405,"lon":404},[408],{"name":409,"role":87,"phone":55,"phoneExt":55,"email":410},"Ron Gansevoort, Prof.","researchnefrologie@int.umcg.nl",{"facility":412,"status":95,"city":413,"state":55,"zip":55,"country":400,"countryCode":401,"cosmosGeoPoint":414,"geoPoint":418,"contacts":419},"Leids Universitair Medisch Centrum","Leiden",{"type":100,"coordinates":415},[416,417],4.49306,52.15833,{"lat":417,"lon":416},[420],{"name":421,"role":87,"phone":55,"phoneExt":55,"email":422},"Siebe Spijker, MD","researchcoordinator_krig_int@lumc.nl",{"facility":424,"status":95,"city":425,"state":55,"zip":55,"country":400,"countryCode":401,"cosmosGeoPoint":426,"geoPoint":430,"contacts":431},"Erasmus Universitair Medisch Centrum Rotterdam","Rotterdam",{"type":100,"coordinates":427},[428,429],4.47917,51.9225,{"lat":429,"lon":428},[432],{"name":433,"role":87,"phone":55,"phoneExt":55,"email":434},"Mahdi Salih, MD","tb.ig@erasmusmc.nl",{"facility":436,"status":95,"city":437,"state":55,"zip":55,"country":438,"countryCode":439,"cosmosGeoPoint":440,"geoPoint":444,"contacts":445},"Fundacio Hospital Universitari Vall D'Hebron Institut De Recerca","Barcelona","Spain","ES",{"type":100,"coordinates":441},[442,443],2.15899,41.38879,{"lat":443,"lon":442},[446],{"name":447,"role":87,"phone":55,"phoneExt":55,"email":448},"Laia Sans Axter, MD","assajos.nefrologia@vhir.org",{"facility":450,"status":95,"city":437,"state":55,"zip":55,"country":438,"countryCode":439,"cosmosGeoPoint":451,"geoPoint":453,"contacts":454},"Fundacio Puigvert",{"type":100,"coordinates":452},[442,443],{"lat":443,"lon":442},[455],{"name":456,"role":87,"phone":55,"phoneExt":55,"email":457},"Roser Torra Balcells, Prof.","ofgrin@fundacio-puigvert.es",{"type":459,"investigatorFullName":460,"investigatorTitle":461,"investigatorAffiliation":462,"oldNameTitle":55,"oldOrganization":55},"PRINCIPAL_INVESTIGATOR","Roman Müller","Prof. Dr. med.","University Hospital of Cologne",[464],{"name":465,"class":6},"German Research Foundation","100614514",false,"NCT07280585","STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease","STOP-PKD","Inclusion Criteria:\n\n* Male and female patients with ADPKD (modified Ravine criteria) ≥ 18 and ≤ 60 years\n* Patients 18 - 39 years: eGFR ≥25 ml\u002Fmin; patients 40 - 60 years: eGFR ≥25 and \\\u003C90 ml\u002Fmin\u002F1.73 m2\n* Indicators of rapid progression, either of the following:\n* Mayo class 1D-E\n* Mayo class 1C AND EITHER\n\n  1. Truncating PKD1 mutation OR\n  2. eGFR loss \\> 3ml\u002Fmin\u002Fyear (determined by ≥ 4 creatinine values within 4 years, ≥ 6 months measurement intervals) OR\n  3. PROPKD score \\> 6 (patient history)\n* IF patient is on ACE-I \u002FARBs: stable dose for 4 weeks before screening\n\nExclusion Criteria:\n\n* Treatment with tolvaptan, somatostatin analogue, lithium or SGLT2i within the last 3 months before screening\n* Medical history of diabetic ketoacidosis, necrotizing fasciitis or organ transplantation\n* Diabetes mellitus type 1 or any type of diabetes mellitus due to insulin deficiency\n* Uncontrolled ongoing urinary tract or genital infections\n* Known intolerance of the study medication ingredients\n* Uncontrolled grade 2 hypertension (\\>160\u002F100 mmHg)\n* Symptomatic hypotension, or systolic blood pressure \\\u003C90 mmHg\n* Primary renal disease other than ADPKD\n* Hepatic impairment (aspartate transaminase \\[AST\\] or alanine transaminase \\[ALT\\]\\>3x the up-per limit of normal \\[ULN\\]; or total bilirubin \\>2x ULN at time of enrolment)\n* Pregnancy, breastfeeding or women of child-bearing potential not using effective contraception method\n* Not able to comply with the study protocol, in the investigator's judgement\n* Not able to provide informed consent\n* Participation in any other interventional clinical trial in the last 2 months","ALL","18 Years","60 Years",{"count":476,"type":477},420,"ESTIMATED","INTERVENTIONAL",[480],"PHASE3","Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.",[483],"Polycystic Kidney, Autosomal Dominant",[470,485,486,487,488,489,490,491,492,493],"ADPKD","Dapagliflozin","SGLT2","PKD","polycystic kidney disease","SGLT2i","sodium-glucose","sodium glucose","Phase 3","2026-06-12",{"date":496,"type":497},"2026-06-15","ACTUAL",{"date":499,"type":497},"2025-12-16",{"date":501,"type":477},"2030-05-15",{"name":5,"class":6},30]